Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations
NCT05019794
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
80
Enrollment
INDUSTRY
Sponsor class
Conditions
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Solid Tumor
Interventions
DRUG:
Infigratinib
Sponsor
LianBio LLC